Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting to University of Maryland Rehabilitation and Orthopaedic Institute for total shoulder arthroplasty (TSA) or reverse TSA~* Primary language is English~Exclusion Criteria:~* Allergy to either ropivacaine or bupivacaine~* On chronic opioid therapy at the time of evaluation~* Pre-existing neurologic condition which precludes the use of regional anesthesia~* Unable to provide consent as determined by the operating surgeons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TSA - Liposomal Bupivacaine Infiltration (Type: ACTIVE_COMPARATOR): Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
- Reverse TSA - Liposomal Bupivacaine Infiltration (Type: ACTIVE_COMPARATOR): Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
- TSA - Continuous Perineural Ropivacaine Infusion (Type: ACTIVE_COMPARATOR): Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
- Reverse TSA - Continuous Perineural Ropivacaine Infusion (Type: ACTIVE_COMPARATOR): Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.

Based on this trial design, predict the completion outcome and termination type (if applicable).